In conclusion, the present findings confirm that de novo heterozygous variants of SEMA6B underlie an autosomal dominant type of myoclonic epilepsy with variable severity and different response to anti-epileptic treatment. The gene discussed is SEMA6B; the disease is myoclonic epilepsy.